EVMN Evommune, Inc. Insider Trading

EVMN Director Hopfner bought 1,000 shares at $17.35; stock now $17.11, -22.0% from 52-week high

Director Robert Lorne Hopfner purchased 1,000 shares of Evommune at $17.35, increasing his holdings from 3,026 to 4,026 shares. The company is unprofitable with net income of $-12.5M against quarterly revenue of $10.0M, while the stock trades 22.0% below its 52-week high of $21.93. Hopfner's cross-ticker track record shows 4 prior buys with an average 90-day return of -31.3% and a 0% win rate, providing context on the historical outcome pattern of his open-market purchases. This purchase occurs in a declining-price environment without any material corporate developments disclosed in the filing to explain the timing.

RA Capital Management (Director) purchases 1,250,000 shares at $16.00 ($20.0M) in EVMN; cluster pattern with 2 other insiders buying in past 14 days

RA Capital Management, L.P., a director of Evommune, Inc., executed 2 separate purchases totaling 1,250,000 shares (1.25M shares) for $20,000,000.00 at a blended average price of $16.00 per share on November 7, 2025. The filing reveals a derivative-conversion transaction; the insider's full position in derivative securities (Table II) is not yet populated in the database, so the post-transaction Table I holding of 784,345 shares does not represent the complete position. Most significantly, this purchase occurs within a cluster pattern: 2 other insiders also bought within the past 14 days, indicating coordinated insider accumulation at a newly listed company (EVMN listed 5 trading days prior). The current stock price of $19.52 as of November 12, 2025 represents a 22% premium to the $16.00 transaction price, though the recency of listing means longer-term price context is unavailable.

LSP 7 Cooperative UA (10% owner) purchases 1,562,500 shares of EVMN at $16.00 for $25,000,000 in cluster-buy pattern

LSP 7 Cooperative UA, a 10% shareholder in Evommune, acquired 1,562,500 shares at $16.00 on 2025-11-07, expanding its holding from 3,367,133 shares to 4,929,633 shares—a 46.4% increase in position size. This $25,000,000 transaction occurs just 5 trading days after EVMN's listing, when the company is establishing its post-IPO market valuation. The timing coincides with a broader pattern: 2 other insiders also bought within the past 14 days, suggesting coordinated conviction at the post-IPO stage. While the current price has risen to $19.52 above the transaction price of $16.00, the clustering of insider purchases across multiple parties within two weeks post-listing signals material confidence in near-term prospects. However, caution is warranted: this is a very early-stage public company, derivatives-conversion elements are present in the filing (Form 4 Table II), and the shareholder's full position cannot yet be fully assessed from available data.

Director Verduyn-van Weegen bought 1,562,500 shares of EVMN at $16.00 for $25,000,000; cluster pattern: 2 other insiders also bought within 14 days.

Director Felice Isabel Verduyn-van Weegen purchased 1,562,500 shares of Evommune at $16.00 on 2025-11-07, increasing her holdings to 4,929,633 shares (a +46.4% increase from 3,367,133 shares pre-transaction). The $25,000,000 transaction represents a substantial capital commitment by an insider during the company's recent listing phase (5 trading days since IPO). This purchase is part of a cluster buy pattern, with 2 other insiders also acquiring shares within the past 14 days, indicating coordinated or independently motivated insider accumulation. The current stock price of $19.52 as of 2025-11-12 is elevated relative to the $16.00 transaction price, though given the company's very recent listing status, longer-term trading patterns are not yet established. The presence of derivative holdings flagged in Table II warrants caution against interpreting the Table I position as the insider's total stake.